As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

The statement confused experts who said that vaccines aimed at new pathogens have always been tested this way. "That has been ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...